Alnylam Pharmaceuticals, Inc. (ALNY) Given a $90.00 Price Target at Ladenburg Thalmann Financial Services
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been given a $90.00 price target by research analysts at Ladenburg Thalmann Financial Services in a research note issued to investors on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Ladenburg Thalmann Financial Services’ target price would indicate a potential upside of 15.76% from the company’s previous close.
Other research analysts have also issued reports about the stock. UBS AG began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 29th. They set a “neutral” rating and a $55.00 target price on the stock. Morgan Stanley restated an “equal weight” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, July 10th. Chardan Capital set a $95.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 5th. BMO Capital Markets started coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, April 17th. They issued an “outperform” rating and a $73.00 price target on the stock. Finally, Vetr lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 price target on the stock. in a research report on Monday, May 15th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $78.83.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 1.26% during midday trading on Monday, reaching $77.75. The company’s stock had a trading volume of 728,324 shares. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $86.92. The company has a 50 day moving average of $73.05 and a 200-day moving average of $53.57. The stock’s market capitalization is $6.70 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The firm had revenue of $19 million for the quarter, compared to analyst estimates of $22.91 million. During the same quarter last year, the firm earned ($1.21) earnings per share. The company’s revenue was up 160.3% compared to the same quarter last year. Equities research analysts predict that Alnylam Pharmaceuticals will post ($5.24) earnings per share for the current year.
In other Alnylam Pharmaceuticals news, major shareholder Sanofi acquired 297,501 shares of the company’s stock in a transaction dated Wednesday, May 31st. The stock was bought at an average price of $71.87 per share, with a total value of $21,381,396.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael Mason sold 9,375 shares of the stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $70.00, for a total transaction of $656,250.00. Following the completion of the sale, the vice president now directly owns 5,625 shares of the company’s stock, valued at approximately $393,750. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 64,125 shares of company stock worth $4,325,000. 4.30% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in ALNY. Dodge & Cox acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $344,633,000. BlackRock Inc. raised its stake in Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares during the last quarter. Perceptive Advisors LLC raised its stake in Alnylam Pharmaceuticals by 831.4% in the first quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock valued at $56,553,000 after buying an additional 985,000 shares during the last quarter. Norges Bank acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $24,885,000. Finally, Rockefeller Financial Services Inc. raised its stake in Alnylam Pharmaceuticals by 4,724.4% in the first quarter. Rockefeller Financial Services Inc. now owns 506,223 shares of the biopharmaceutical company’s stock valued at $25,944,000 after buying an additional 495,730 shares during the last quarter. 89.22% of the stock is owned by institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.